The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

BACCARANI, M., F. CASTAGNETTI, G. GUGLIOTTA, G. ROSTI, S. SOVERINI, A. ALBEER and M. PFIRRMANN. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. London: Nature Publishing Group, 2019. ISSN 0887-6924.

Basic information

• Original name: The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
• Authors: BACCARANI, M., F. CASTAGNETTI, G. GUGLIOTTA, G. ROSTI, S. SOVERINI, A. ALBEER and M. PFIRRMANN.
• Edition: Leukemia, London, Nature Publishing Group, 2019, 0887-6924.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30205 Hematology
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 8.665
• Organization unit: Faculty of Medicine
• Tags: International impact, Reviewed

Abstract

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and el 3a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients >= 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients >= 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.